Lucid Diagnostics Inc. (LUCD)
NASDAQ: LUCD · Real-Time Price · USD
0.9786
-0.0314 (-3.11%)
At close: Jul 31, 2025, 4:00 PM
0.9899
+0.0113 (1.15%)
After-hours: Jul 31, 2025, 5:58 PM EDT
Company Description
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States.
The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients.
The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Lucid Diagnostics Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 14, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 72 |
| CEO | Lishan Aklog |
Contact Details
Address: 360 Madison Avenue, 25th Floor New York, New York 10017 United States | |
| Phone | 917 813 1828 |
| Website | luciddx.com |
Stock Details
| Ticker Symbol | LUCD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001799011 |
| CUSIP Number | 54948X109 |
| ISIN Number | US54948X1090 |
| Employer ID | 82-5488042 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lishan Aklog M.D. | Chairman and Chief Executive Officer |
| Shaun M. O'Neill M.B.A. | President and Chief Operating Officer |
| Michael Adam Gordon | General Counsel and Secretary |
| Dr. Sanford D. Markowitz M.D., Ph.D. | Co-Founder and Strategic Advisor |
| Dr. Joseph Willis M.D. | Co-founder and Strategic Advisor |
| Dr. Amitabh Chak M.D. | Co-Founder and Strategic Advisor |
| Helen Moinova Ph.D. | Co-Founder and Strategic Advisor |
| Dr. Brian J. deGuzman M.D. | Chief Technology and Compliance Officer |
| Dr. Suman M. Verma M.D., Ph.D. | Chief Scientific Officer |
| Matthew Riley | Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 18, 2025 | 8-K | Current Report |
| Jun 3, 2025 | 424B3 | Prospectus |
| May 30, 2025 | EFFECT | Notice of Effectiveness |
| May 30, 2025 | 8-K | Current Report |
| May 30, 2025 | 424B5 | Filing |
| May 27, 2025 | UPLOAD | Filing |
| May 22, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| May 14, 2025 | 8-K | Current Report |
| May 13, 2025 | 10-Q | Quarterly Report |
| Apr 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |